Crypto News: New Coverage: See Why (ONCO) Just Landed On Tomorrow’s Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Daily Edge Report Announces (ONCO) On Tomorrow's

Watchlist—Thursday, February 12, 2026

Don't miss the next breakout — get real-time alerts sent straight to your phone!

Consider Starting Your Own Research On (ONCO) Before Tomorrow Morning

February 11, 2026

New Coverage: See Why (ONCO) Just Landed On Tomorrow's Radar

Dear Reader,

For years, prostate care has lived in a gray zone, too many men caught between "wait and see" and invasive intervention, often without the precision tools to confidently guide the decision.

That's starting to change.

A new wave of diagnostics and targeted therapies is moving prostate health out of uncertainty and into a more data-driven era. The focus is shifting toward smarter screening, clearer clinical signals, and treatment pathways designed to better match the right action to the right patient at the right time.

The potential behind that shift is substantial.

The global benign prostatic hyperplasia (BPH) treatment market is forecasted to top $13B in 2026 and expand more than 60% to exceed $21B by 2034. At the same time, the global prostate cancer diagnostics market is projected to surpass $10B in 2026 and grow roughly 70% to over $17B by 2034.

Onconetix, Inc. (Nasdaq: ONCO) is positioning itself directly inside this expanding landscape. The company is pursuing a dual-track strategy that combines therapeutics and diagnostics, aiming to improve how prostate health decisions are evaluated and executed.

That strategic alignment with two high-growth segments is one of the reasons (ONCO) is set to top our watchlist tomorrow morning — Thursday, February 12, 2026.

There's also a structural factor worth noting.

(ONCO) has fewer than 1.3M shares available to the public. When floats are this tight, shifts in attention can translate quickly.

Currently trending below $1.50, (ONCO) appears to be flying under many broader screens.

And when emerging healthcare themes intersect with small-float dynamics, things can start to move, sometimes faster than expected.

A Dual-Track Approach to Prostate Health Innovation

Onconetix, Inc. (ONCO) is a commercial-stage biotechnology company focused on developing, commercializing, and expanding innovative therapeutics and diagnostics primarily in men's health and oncology. The firm operates in the United States, the European Union, and other markets, with an emphasis on addressing unmet medical needs around prostate disorders and cancer.

(ONCO)'s product portfolio includes entadfi®, an FDA-approved, once-daily oral therapy designed for the treatment of benign prostatic hyperplasia (BPH). This condition, an enlarged prostate that affects urinary function, impacts millions of men worldwide, and entadfi's formulation combines established mechanisms to improve symptom relief and patient compliance.

(ONCO)'s flagship test is proclarix®, a proprietary in vitro diagnostic system for prostate cancer. Approved for use in Europe under CE IVDR standards, proclarix analyzes multiple biomarkers in blood serum to assess a patient's risk of clinically significant prostate cancer, helping clinicians reduce unnecessary biopsies and improve diagnostic accuracy.

To support growth and expand its scientific reach, Onconetix acquired Proteomedix AG, the developer of proclarix, and has engaged in licensing arrangements through this subsidiary to bolster broader diagnostic capabilities, including partnerships on pancreatic cancer testing reagents.

The company has also pursued financing and strategic transactions to strengthen its balance sheet. For example, in 2025 Onconetix completed a $12.9M private placement of preferred shares and warrants to support working capital and corporate initiatives, including previously contemplated but subsequently terminated merger discussions with other biotech firms.

Overall, (ONCO)'s dual focus on both therapeutics that treat symptoms and conditions and diagnostics that improve clinical decision-making positions it as a participant in evolving waves of precision care within men's health and oncology.

Expanding Market Runway Backed by Clinical Data

The market for prostate health is substantial: the benign prostatic hyperplasia (BPH) treatment market is estimated to top $13B in 2026 and is projected to exceed $21B by 2034, while the prostate cancer diagnostics market is forecast to top $10B in 2026 and grow to more than $17B by 2034.

(ONCO) has secured a competitive edge through clinical validation, with PROCLARIX® being included in both European and American urology guidelines.

This recognition is critical, as it supports the clinical utility of the test in cases where MRI results are uncertain. By reducing unnecessary biopsies, (ONCO) is not only improving patient outcomes but also addressing significant costs within the healthcare system.

Key Developments Driving the Story

Clinical Validation for Proclarix®: (ONCO) announced positive validation data for its Proclarix® prostate cancer blood test in a Danish cohort of more than 800 patients, with results presented at the 2025 European Association of Urology Congress.

EAU Congress Presentation: New clinical data for Proclarix was accepted for presentation at the 2025 EAU Congress, supporting continued visibility in the urology community.

$12.9M Private Placement: (ONCO) completed a $12.9M Series D preferred fin-an-cing, strengthening its balance sheet.

Nasdaq Compliance Update: (ONCO) received a favorable Nasdaq Hearings Panel decision and implemented a reverse share split to address minimum bid requirements.

7 Factors Putting (ONCO) on Our Radar for Thursday, February 12, 2026

1. Tight Share Structure: With fewer than 1.3M shares available to the public, (ONCO)'s limited float means shifts in attention can translate quickly if demand shifts.

2. Below Key Screening Levels: Currently trending under $1.50, the shares sit beneath many standard screening thresholds, which can reduce visibility across broader scans.

3. Short-Term Technical Watch: (ONCO) is now trading above its 5-day moving average, a development that may point to emerging near-term momentum.

4. Exposure to Expanding Prostate Markets: (ONCO) operates in prostate health segments projected to reach $13B and $10B in 2026, with growth forecasts of more than 60%–70% through 2034.

5. Clinical Guideline Recognition: PROCLARIX® is referenced in both European and American urology guidelines, supporting its relevance in real-world decision-making for uncertain PSA cases.

6. Two-Pronged Model: Unlike single-asset peers, (ONCO) pairs an FDA-approved therapeutic with a proprietary diagnostic test, spanning multiple stages of prostate care.

7. Commercial-Stage Execution: Recent developments have moved the company beyond pure development, with active commercial rollout of its lead therapy and expanded availability of its diagnostic platform.

Consider Starting Your Own Research On (ONCO) Before Tomorrow Morning

Onconetix, Inc. (Nasdaq: ONCO) has transitioned from development mode to commercial execution. With regulatory groundwork and clinical validation largely in place, the company's focus is now centered on expanding adoption and scaling revenue channels.

The commercial rollout of ENTADFI® and the strategic partnership with Labcorp for PROCLARIX® form the two core drivers to watch in the quarters ahead. Together, they position the company across both treatment and diagnostic decision points within prostate care.

At the same time, the broader medical landscape continues shifting toward active surveillance, risk stratification, and precision-based testing, aiming to reduce unnecessary procedures while improving patient outcomes. (ONCO)'s therapeutic and diagnostic offerings are structured to align with that evolving standard of care.

For those monitoring emerging names operating at the intersection of oncology and personalized medicine, (Nasdaq: ONCO) represents a developing commercial story with multiple levers in play.

As updates continue around commercialization efforts and European initiatives, this remains one under-followed name on our active watchlist.

We'll be watching (ONCO) closely tomorrow morning.

Consider reviewing it before the session begins, and stay tuned for the next update.

Sincerely,

Joel Locke

Senior Editor

The Daily Edge Report

^{DailyEdgeReport.com}^{("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

^{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 02/11/2026 and ending on 02/12/2026 to publicly disseminate information about (ONCO:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC eight thousand USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (ONCO:US).}

^{Please see important disclosure information here:}^{https://dailyedgereport.com/disclosure/onco-o2se5/#details}